Table 1 Population characteristics (N = 125)
From: The molecular tumor burden index as a response evaluation criterion in breast cancer
Characteristics | No | Percentage (%) |
|---|---|---|
HER2 status | ||
Positive | 0 | 0.0 |
Negative | 125 | 100.0 |
Hormone receptor status | ||
Positive | 110 | 88.0 |
Negative | 15 | 12.0 |
Age at diagnosis | ||
≤35 | 20 | 16.0 |
35–60 | 96 | 76.8 |
>60 | 9 | 7.2 |
Tumor stage at initial diagnosis | ||
I | 17 | 13.6 |
II | 41 | 32.8 |
III | 32 | 25.6 |
IV | 14 | 11.2 |
Unknown | 21 | 16.8 |
Nuclear grade | ||
1 | 2 | 1.6 |
2 | 56 | 44.8 |
3 | 20 | 16.0 |
Unknown | 47 | 37.6 |
Disease-free survival (months) | ||
≤12 | 24 | 19.2 |
12–24 | 17 | 13.6 |
24–60 | 43 | 34.4 |
>60 | 40 | 32.0 |
Unknown | 1 | 0.8 |
Number of metastatic sites | ||
1 | 33 | 26.4 |
2–3 | 72 | 57.6 |
≥4 | 22 | 17.6 |
Visceral metastases | ||
Yes | 41 | 32.8 |
No | 86 | 68.8 |
Previous endocrine therapy (after confirmed tumor relapse) | ||
Yes | 33 | 26.4 |
No | 92 | 73.6 |
